VMAT2 (vesicular monoamine transporter 2) is essential for packaging dopamine, serotonin, and other monoamines into synaptic vesicles for release. VMAT2-expressing neurons are fundamental to monoaminergic neurotransmission, and VMAT2 dysfunction contributes to Parkinson's disease, depression, and other neuropsychiatric disorders.
- Dopamine neurons: Substantia nigra, VTA
- Serotonin neurons: Raphe nuclei
- Norepinephrine neurons: Locus coeruleus
- Histamine neurons: Tuberomammillary nucleus
- Synaptic vesicles: Dense-core and small vesicles
- Axonal terminals: High concentration
- Cell bodies: Perinuclear localization
- Dendrites: Release from dendrites
| Marker |
Type |
Function |
| SLC18A2 |
Transporter |
VMAT2 |
| TH |
Enzyme |
Tyrosine hydroxylase |
| TPH2 |
Enzyme |
Tryptophan hydroxylase |
| DBH |
Enzyme |
Dopamine β-hydroxylase |
| SYN1 |
Synaptic |
Synapsin I |
| VAMP2 |
SNARE |
Synaptobrevin-2 |
- Vesicular uptake: H+-gradient dependent
- Quantal release: Regulated release
- Reuse efficiency: Multiple release cycles
- Neuroprotection: Sequester dopamine from cytosol
- Activity-dependent release: Calcium-triggered
- Vesicle pools: Readily releasable and reserve
- Fusion machinery: SNARE complex
- Endocytosis: Vesicle recycling
- Oxidative stress: Protect from auto-oxidation
- Enzymatic breakdown: Sequester from MAO
- Neurotoxicity: Reduce ROS generation
VMAT2 in PD:
- Early reduction: VMAT2 decline in early PD
- Neuroprotection: Reduced packaging increases vulnerability
- Treatment target: VMAT2 enhancers
- Imaging marker: PET ligands for VMAT2
VMAT2 in depression:
- Vesicular dysfunction: Reduced monoamine availability
- Therapeutic target: Enhance function
- SSRI effects: Indirect modulation
- Treatment resistance: Possible role
VMAT2 in ADHD:
- Dopamine dysregulation: Altered packaging
- Reward circuitry: Reward processing deficits
- Therapeutic approaches: Stimulant effects
VMAT2 in addiction:
- Amphetamine effects: Substrate for VMAT2
- Vesicular depletion: Effects on neurotransmission
- Withdrawal: Monoamine depletion
- Vesicle acidification: pH gradient requirement
- ATP dependence: Energy-intensive process
- Mitochondrial function: Supply ATP
- Dopamine oxidation: Cytosolic dopamine toxic
- Autoxidation: Reduced sequestration increases
- ROS generation: Mitochondrial damage
- Protein trafficking: ER-Golgi processing
- Vesicle biogenesis: Synthesis pathway
- Endosomal sorting: Lysosomal degradation
| Region |
Monoamine |
Function |
| Substantia nigra |
Dopamine |
Motor control |
| VTA |
Dopamine |
Reward |
| Raphe nuclei |
Serotonin |
Mood |
| Locus coeruleus |
Norepinephrine |
Arousal |
- VMAT2 enhancers: Increase function
- Lobeline: VMAT2 agonist
- Gene therapy: Restore expression
- Neuroprotective agents: Preserve neurons